Tilelizumab Combined With Nab-Paclitaxel for High-Risk Non-Muscle-Invasive Urothelial Bladder Carcinoma Which is Not Completely Resectable: a Multi-center Study

NCT05418309 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

63

Enrollment

OTHER

Sponsor class

Conditions

High-Risk Non-Muscle Invasive Bladder Urothelial Carcinoma

Interventions

DRUG: Tislelizumab Nab paclitaxel

Sponsor

Tianjin Medical University Second Hospital